Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan

The coronavirus disease (COVID-19) pandemic continues to threaten global public health. Remdesivir and monoclonal antibodies have shown promise for COVID-19 treatment of patients who are immunocompromised, including those with cancer, transplant recipients, and those with autoimmune disorder. Howeve...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jun Hirai, Nobuaki Mori, Daisuke Sakanashi, Wataru Ohashi, Yuichi Shibata, Nobuhiro Asai, Hideo Kato, Mao Hagihara, Hiroshige Mikamo
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2023-09-01
Series:	Viruses
Assuntos:	COVID-19 immunocompromised remdesivir monoclonal antibodies combination
Acceso en liña:	https://www.mdpi.com/1999-4915/15/9/1952
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!